CRESCENT BIOPHARMA INC (CBIO) Stock News

USA - Nasdaq - NASDAQ:CBIO - KYG2545C1042 - Common Stock

13.07 USD

+0.08 (+0.62%)

Last: 12/5/2025, 8:06:52 PM

12.85 USD

-0.22 (-1.68%)

After Hours: 12/5/2025, 8:06:52 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CBIO Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Stocktwits

The Deal That Sent Crescent Biopharma Shares Surging Over 40% Pre-Market Today

4 days ago - By: Crescent Biopharma, Inc.

Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors

4 days ago - By: Crescent Biopharma, Inc.

Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors

4 days ago - By: Crescent Biopharma, Inc.; Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics

4 days ago - By: Crescent Biopharma, Inc.; Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics

20 days ago - By: Crescent Biopharma

Crescent Biopharma Announces Grants of Inducement Awards

20 days ago - By: Crescent Biopharma

Crescent Biopharma Announces Grants of Inducement Awards

a month ago - By: Crescent Biopharma

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

a month ago - By: Crescent Biopharma

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

a month ago - By: Crescent Biopharma

Crescent Biopharma to Present at November Investor Conferences

a month ago - By: Crescent Biopharma

Crescent Biopharma to Present at November Investor Conferences

a month ago - By: Crescent Biopharma

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

a month ago - By: Crescent Biopharma

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

3 months ago - By: Crescent Biopharma

Crescent Biopharma to Present at September Investor Conferences

3 months ago - By: Crescent Biopharma

Crescent Biopharma to Present at September Investor Conferences

3 months ago - By: Benzinga - Mentions: DVN FIG GTES AMBQ

This Devon Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

4 months ago - By: Benzinga - Mentions: ALM ARM INVA

This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday

4 months ago - By: Crescent Biopharma

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

4 months ago - By: Crescent Biopharma

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

5 months ago - By: Crescent Biopharma

Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

6 months ago - By: Crescent Biopharma

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

6 months ago - By: Crescent Biopharma

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

2 years ago - By: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split